- Home
- Signaling Pathways
- GPCR/G protein
- S1P receptor
- BAF312 (Siponimod)
- Home
- Biochemical Reagent
- Signaling pathways
- GPCR
- G Protein
- BAF312 (Siponimod)
BAF312 (Siponimod)
Siponimod (BAF312; CAS 1230487-00-9) is a selective sphingosine 1-phosphate (S1P) receptor modulator with potent agonist activity at S1P1 (EC50 = 0.39 nM) and S1P5 (EC50 = 0.98 nM) receptors, demonstrating over 1000-fold selectivity for S1P1 compared to S1P2, S1P3, and S1P4 receptors. Preclinical studies in Lewis rats have shown that Siponimod reduces peripheral lymphocyte counts dose-dependently. Siponimod serves as an important tool for studying immune cell trafficking and evaluating therapeutic strategies targeting sphingosine-mediated signaling.
| Storage | Store at -20°C |
| M.Wt | 516.6 |
| Cas No. | 1230487-00-9 |
| Formula | C29H35F3N2O3 |
| Solubility | ≥194.8 mg/mL in DMSO; insoluble in H2O; ≥3.27 mg/mL in EtOH |
| Chemical Name | 1-[[4-[(E)-N-[[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy]-C-methylcarbonimidoyl]-2-ethylphenyl]methyl]azetidine-3-carboxylic acid |
| SDF | Download SDF |
| Canonical SMILES | CCC1=C(C=CC(=C1)C(=NOCC2=CC(=C(C=C2)C3CCCCC3)C(F)(F)F)C)CN4CC(C4)C(=O)O |
| Shipping Condition | Small Molecules with Blue Ice, Modified Nucleotides with Dry Ice. |
| General tips | We do not recommend long-term storage for the solution, please use it up soon. |
| Cell experiment [1]: | |
|
Cell lines |
human atrial myocytes |
|
Preparation method |
This compound is soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
0.001-1000 nM |
|
Applications |
In human atrial myocytes, BAF312 concentration-dependently increased GIRK current amplitude with EC50 value of 15.8 nM and reached approximately 80% of the carbachol-induced maximal current activation. |
| Animal experiment [1, 2]: | |
|
Animal models |
rat experimental autoimmune encephalomyelitis (EAE) model; Lewis rats |
|
Dosage form |
0.03, 0.3 or 3 mg/kg, orally administrated, 24 day; 1 mg/kg, orally administrated |
|
Application |
In rat experimental autoimmune encephalomyelitis (EAE) model, BAF312 starting on day 11 significantly inhibited established neurological deficits. BAF312 at 0.3 or 3 mg/kg caused a significant reduction of disease scores (AUC (area under the concentration–time curve) from days 12 to 34). In Lewis rats, BAF312 (Siponimod) (1 mg/kg) dose-dependently reduced peripheral lymphocyte counts. At the Tmax of 8 h postadministration, the lymphocyte counts were decreased by 88%. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Gergely P1, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, Pan S, Gray NS, Hinterding K, Cooke NG, Groenewegen A, Vitaliti A, Sing T, Luttringer O, Yang J, Gardin A, Wang N, Crumb WJ Jr, Saltzman M, Rosenberg M, Wallstrm E. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012 Nov;167(5):1035-47. [2] Pan S1, Gray NS1, Gao W1, Mi Y1, Fan Y1, Wang X1, Tuntland T1, Che J1, Lefebvre S1, Chen Y1, Chu A1, Hinterding K2, Gardin A2, End P2, Heining P2, Bruns C2, Cooke NG2, Nuesslein-Hildesheim B2 .Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013 Jan 4;4(3):333-7. |
|
| Description | BAF312 is a potent and selective agonist of S1P with EC50 value of 0.39nM for S1P1 receptors and 0.98nM for S1P5 receptors, respectively | |||||
| Targets | S1P1 receptors | S1P5 receptors | ||||
| IC50 | 0.39nM (EC50) | 0.98nM (EC50) | ||||
Quality Control & MSDS
- View current batch:
Chemical structure
Related Biological Data
Related Biological Data
